Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 2/20 | 0.67 |
| ▸ | ECE1 | P42892 | 7/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | MPO | P05164 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | BLM | P54132 | 1/20 | 0.62 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.62 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.61 |
| ▸ | LTA4H | P09960 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9852029 | 1.00 | ACE (0.67) | ACEECE1KDM4EMEN1LMNA | |
| SCHEMBL30195254 | 0.94 | ACE (0.59) | ACEECE1KDM4EMEN1LMNA | |
| SCHEMBL30389278 | 0.93 | ACE (0.58) | ACEECE1KDM4EMEN1LMNA | |
| SCHEMBL30123058 | 0.92 | ACE (0.63) | ACEECE1ALOX15 | |
| SCHEMBL14941216 | 0.92 | ACE (0.68) | ACEECE1KDM4EMEN1LMNA | |
| SCHEMBL29603940 | 0.92 | ACE (0.68) | ACEECE1KDM4EMEN1LMNA | |
| SCHEMBL7422711 | 0.92 | ACE (0.68) | ACEECE1KDM4EMEN1LMNA | |
| SCHEMBL31606512 | 0.92 | ECE1 (0.65) | ACEECE1KDM4EMEN1LMNA | |
| SCHEMBL30390486 | 0.92 | ACE (0.63) | ACEECE1 | |
| SCHEMBL30724706 | 0.91 | ACE (0.62) | ACEECE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-121577769-A | Urine metabolism marker composition for diagnosing kidney cancer and application thereof | 哈尔滨脉图精准技术有限公司 | 2026-02-27 | — | — | CN | claimed |
| CN-103694314-B | Preparation method of active peptide with snake venom source | SHANGHAI INST PHARM INDUSTRY | 2015-03-25 | — | — | CN | claimed |
| EP-0457314-A1 | Nutrient compositions containing peptides | CLINTEC NUTRITION COMPANY (US) | 1991-11-21 | — | — | EP | claimed |
| EP-4713368-A1 | ANTI-CD28 ANTIBODIES AND METHODS RELATED THERETO | Adimab, LLC (US) | 2026-03-25 | — | — | EP | disclosed |
| EP-3604503-B1 | ADDITIVE FOR UNDIFFERENTIATION MAINTAINING MEDIUM | AJINOMOTO KK (JP) | 2026-03-18 | — | — | EP | disclosed |
| CN-121577769-A | Urine metabolism marker composition for diagnosing kidney cancer and application thereof | 哈尔滨脉图精准技术有限公司 | 2026-02-27 | — | — | CN | disclosed |
| US-20260043020-A1 | BINDING MEMBERS WITH ALTERED DIVERSITY SCAFFOLD DOMAINS | Maxion Therapeutics Limited (GB) | 2026-02-12 | — | — | US | disclosed |
| US-20250333464-A1 | IL10 AGONISTS AND METHODS OF USE THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2025-10-30 | — | — | US | disclosed |
| US-20250270512-A1 | ADDITIVE FOR UNDIFFERENTIATION MAINTAINING MEDIUM | AJINOMOTO CO., INC. (JP) | 2025-08-28 | — | — | US | disclosed |
| CN-119120419-B | Antarctic krill dehalogenase and application thereof in degradation of haloalkane compounds | 中国水产科学研究院黄海水产研究所 | 2025-05-06 | — | — | CN | disclosed |
| CN-119661673-A | Cold-resistance negative regulation gene OsbHLH090 of rice and application thereof | 南京农业大学 | 2025-03-21 | — | — | CN | disclosed |
| US-11673930-B2 | IL10 agonists and methods of use thereof | Regeneran Pharmaceuticals, Inc. (US) | 2023-06-13 | — | — | US | disclosed |
| CN-114137226-B | Early diagnosis marker for cerebral infarction, screening method and application thereof, and construction method and application of early diagnosis model for cerebral infarction | 首都师范大学 | 2023-04-28 | — | — | CN | disclosed |
| CN-115976203-A | Application of HAP1 in preparation of products for diagnosing, preventing and/or treating gastric cancer | 威海市立医院 | 2023-04-18 | — | — | CN | disclosed |
| WO-2023027164-A1 | REACTIVE OXYGEN SPECIES (ROS) PRODUCTION PROMOTER | 株式会社ペルセウスプロテオミクス | 2023-03-02 | — | — | WO | disclosed |
| CN-114478789-A | anti-PD-L1 and OX40 bispecific antibodies and uses thereof | 安徽安科生物工程（集团）股份有限公司 | 2022-05-13 | — | — | CN | disclosed |
| CN-114431485-A | Microecological preparation for preventing colorectal cancer and application thereof | 刘如石 | 2022-05-06 | — | — | CN | disclosed |
| US-20200040308-A1 | ADDITIVE FOR UNDIFFERENTIATION MAINTAINING MEDIUM | AJINOMOTO CO., INC. (JP) | 2020-02-06 | — | — | US | disclosed |
| EP-3604503-A1 | ADDITIVE FOR UNDIFFERENTIATION MAINTAINING MEDIUM | Ajinomoto Co., Inc. (JP) | 2020-02-05 | — | — | EP | disclosed |
| CN-103694314-B | Preparation method of active peptide with snake venom source | SHANGHAI INST PHARM INDUSTRY | 2015-03-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260043020-A1 | BINDING MEMBERS WITH ALTERED DIVERSITY SCAFFOLD DOMAINS | VSIG8, CDR2, VSIR | ACE 4878/4885ECE1 4635/4885KDM4E 4689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.